Certain MT1 agonists, including Agomelatine, Ramelteon, and Tasimelteon that are used clinically for sleep disorders (Kato et al., 2005; Kuriyama et al., 2014; Liu et al., 2016), have the potential to inhibit neuroinflammation, further remitting neuron loss and alleviate motor symptoms in PD or other neurodegenerative diseases like AD. Here, MTNR1A is linked to Parkinson disease.